(Q35753417)

10 August 2017

1 reference

title

Glatiramer acetate for the treatment of multiple sclerosis (English)

1 reference

10 August 2017

Jerry S Wolinsky

1

1 reference

10 August 2017

language of work or name

English

0 references

publication date

1 April 2004

1 reference

Expert Opinion on Pharmacotherapy

10 August 2017

published in

1 reference

10 August 2017

volume

5

1 reference

10 August 2017

issue

4

1 reference

10 August 2017

page(s)

875-891

1 reference

Glatiramer acetate (Copaxone®) therapy for multiple sclerosis

10 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.4.875

Effect of relapses on development of residual deficit in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.4.875

The use of mitoxantrone (Novantrone) for the treatment of multiple sclerosis: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.4.875

Suppression of experimental allergic encephalomyelitis by a synthetic polypeptide

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.4.875

The effect of Cop 1, a synthetic polypeptide, on chronic relapsing experimental allergic encephalomyelitis in guinea pigs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.4.875

Crystal structure of HLA-DR2 (DRA*0101, DRB1*1501) complexed with a peptide from human myelin basic protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.4.875

Copolymer 1 acts against the immunodominant epitope 82-100 of myelin basic protein by T cell receptor antagonism in addition to major histocompatibility complex blocking

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.4.875

Glatiramer acetate (Copaxone) induces degenerate, Th2-polarized immune responses in patients with multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.4.875

Glatiramer acetate-reactive peripheral blood mononuclear cells respond to multiple myelin antigens with a Th2-biased phenotype.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.4.875

Sustained immunological effects of Glatiramer acetate in patients with multiple sclerosis treated for over 6 years

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.4.875

Specific Th2 cells accumulate in the central nervous system of mice protected against experimental autoimmune encephalomyelitis by copolymer 1

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.4.875

Glatiramer acetate-specific T cells in the brain express T helper 2/3 cytokines and brain-derived neurotrophic factorin situ

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.4.875

Glatiramer acetate-reactive T cells produce brain-derived neurotrophic factor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.4.875

Autoimmune T cells protect neurons from secondary degeneration after central nervous system axotomy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.4.875

T cell immunity to copolymer 1 confers neuroprotection on the damaged optic nerve: possible therapy for optic neuropathies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.4.875

Vaccination for protection of retinal ganglion cells against death from glutamate cytotoxicity and ocular hypertension: implications for glaucoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.4.875

Axonal damage is reduced following glatiramer acetate treatment in C57/bl mice with chronic-induced experimental autoimmune encephalomyelitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.4.875

Glatiramer acetate (Copaxone) regulates nitric oxide and related cytokine secretion in experimental autoimmune encephalomyelitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.4.875

Neurotrophins and neuronal plasticity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.4.875

Glatiramer acetate-specific T-helper 1- and 2-type cell lines produce BDNF: implications for multiple sclerosis therapy. Brain-derived neurotrophic factor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.4.875

Treatment with glatiramer acetate induces specific IgG4 antibodies in multiple sclerosis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.4.875

Antibodies to glatiramer acetate do not interfere with its biological functions and therapeutic efficacy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.4.875

Blocking effects of serum reactive antibodies induced by glatiramer acetate treatment in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.4.875

Interferon-beta antibodies: implications for the treatment of MS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.4.875

Sustained clinical benefits of glatiramer acetate in relapsing multiple sclerosis patients observed for 6 years. Copolymer 1 Multiple Sclerosis Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.4.875

Effects of glatiramer acetate on relapse rate and accumulated disability in multiple sclerosis: meta-analysis of three double-blind, randomized, placebo-controlled clinical trials.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.4.875

European/Canadian multicenter, double-blind, randomized, placebo-controlled study of the effects of glatiramer acetate on magnetic resonance imaging-measured disease activity and burden in patients with relapsing multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.4.875

Short-term brain volume change in relapsing-remitting multiple sclerosis: effect of glatiramer acetate and implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.4.875

Copaxone's effect on MRI-monitored disease in relapsing MS is reproducible and sustained

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.4.875

A retrospective, observational study comparing the four available immunomodulatory treatments for relapsing-remitting multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.4.875

Comparison of glatiramer acetate (Copaxone) and interferon beta-1b (Betaferon) in multiple sclerosis patients: an open-label 2-year follow-up

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.4.875

Copolymer 1 (glatiramer acetate) in relapsing forms of multiple sclerosis: open multicenter study of alternate-day administration

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.4.875

A comparison of observational studies and randomized, controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.4.875

Glatiramer acetate: a review of its use in relapsing-remitting multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.4.875

Additive effects of copolymer-1 and interferon beta-1b on the immune response to myelin basic protein.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.4.875

Oral treatment of mice with copolymer 1 (glatiramer acetate) results in the accumulation of specific Th2 cells in the central nervous system

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.4.875

Immunological assay for assessing the efficacy of glatiramer acetate (Copaxone) in multiple sclerosis. A pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.4.875

Glatiramer acetate treatment in patients with childhood and juvenile onset multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.4.875

Risk-benefit assessment of glatiramer acetate in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.4.875

21 January 2018

Identifiers

DOI

10.1517/14656566.5.4.875

1 reference

10 August 2017

1 reference